Annual Heart and Circulation Checklist

Cardiovascular disease develops slowly over years and decades — the atherosclerotic plaque that causes a heart attack at age 72 began accumulating in the arterial wall at age 45 or earlier. The window for prevention is long, but it requires consistent, systematic attention to a set of measurable cardiovascular risk factors and health parameters that can be tracked, targeted, and improved year over year. An annual heart and circulation checklist provides the framework for this systematic review — ensuring that no important measurement is missed, no medication goes unreviewed, and no emerging risk factor is overlooked simply because it did not produce obvious symptoms.

This annual checklist is designed for adults over 60 and for anyone with established cardiovascular disease, diabetes, or a family history of early heart disease. It covers the laboratory tests, physical measurements, medication reviews, screening procedures, and lifestyle assessments that collectively define comprehensive annual cardiovascular health maintenance. Use it to prepare for your annual physical examination, to prompt conversations with your primary care physician or cardiologist, and to track your cardiovascular health trajectory from year to year.

Laboratory Tests: What to Check Every Year

Comprehensive lipid panel (fasting): a fasting lipid panel measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides. For adults on statin therapy, the annual lipid panel confirms whether LDL is meeting the guideline-recommended target for your risk category. For adults not on statins, it identifies whether LDL has risen to a threshold that warrants treatment initiation. Current targets: LDL below 100 mg/dL for intermediate-risk adults; LDL below 70 mg/dL for adults with established cardiovascular disease, diabetes, or 10-year ASCVD risk above 20%. Non-HDL cholesterol (calculated as total cholesterol minus HDL) is an alternative measure that includes very-low-density lipoprotein particles and may be a better overall atherogenic risk marker than LDL alone — particularly in adults with elevated triglycerides.

HbA1c (glycated hemoglobin): reflects average blood glucose over the past two to three months. For diabetic adults, annual HbA1c monitoring tracks glycemic control and guides medication adjustment. Target HbA1c in most diabetic adults over 65 is below 7.5 to 8% — slightly less aggressive than the below 7% target in younger adults because hypoglycemia in older adults carries serious risks (falls, cardiac arrhythmias, impaired cognition). For pre-diabetic adults (HbA1c 5.7 to 6.4%), annual monitoring tracks whether glycemia is progressing toward diabetes, signaling the need for lifestyle intervention intensification.

Kidney function (creatinine, eGFR, urine albumin-creatinine ratio): chronic kidney disease is a cardiovascular risk-equivalent condition that accelerates atherosclerosis and complicates medication management. Annual eGFR (estimated glomerular filtration rate) tracking identifies CKD progression that may require dose adjustments in ACE inhibitors, ARBs, metformin, and some statins. Urine albumin-creatinine ratio above 30 mg/g (microalbuminuria) is a marker of both renal and vascular endothelial injury that signals increased cardiovascular risk independent of eGFR and warrants consideration of ACE inhibitor or ARB therapy in diabetic and hypertensive patients not already taking these drugs.

Complete blood count: anemia (hemoglobin below 12 g/dL in women, below 13 g/dL in men) contributes to fatigue, reduced exercise tolerance, and compensatory tachycardia — all symptoms that can mimic cardiac disease and that, in patients with established coronary artery disease, can worsen myocardial ischemia. Annual CBC identifies anemia that may be causing or exacerbating cardiovascular symptoms. In patients on anticoagulant therapy (warfarin, apixaban, rivaroxaban) for atrial fibrillation or prior thromboembolism, CBC monitoring also tracks platelet counts and identifies gastrointestinal bleeding that may require anticoagulation dose adjustment.

BNP or NT-proBNP: for adults with established heart failure or significant risk factors for heart failure, annual BNP measurement tracks myocardial wall stress over time. Rising BNP at annual measurement — even without new symptoms — may indicate subclinical deterioration that warrants echocardiography review and medication adjustment before symptomatic decompensation occurs. Many heart failure specialists use annual or semi-annual BNP as a guide to optimize diuretic and neurohormonal therapy proactively.

Physical Measurements: The Annual Numbers That Matter

Blood pressure: blood pressure should be measured at every annual visit — ideally twice in both arms with a validated automated device, after five minutes of seated rest. Document the higher arm reading as your reference. The target for most adults over 60 with hypertension is systolic below 130 mmHg (ACC/AHA 2017 guidelines) or 140 mmHg (for those with significant comorbidities where aggressive control would not be tolerated). Note whether blood pressure is stable, trending up, or trending down compared to last year’s measurements — stable medication dosing in the context of rising blood pressure indicates either medication non-adherence, increasing dietary sodium, weight gain, or progressive arterial stiffening that requires medication intensification.

Resting heart rate: resting heart rate above 80 beats per minute in an adult not on beta blockers may signal inadequate heart failure medication optimization, chronic volume overload, deconditioning, or thyroid dysfunction. Resting heart rate below 50 in a patient on beta blockers and/or digoxin may signal over-treatment, particularly if accompanied by fatigue, exercise intolerance, or dizziness. The annual visit provides the opportunity to assess whether the heart rate achieved on current therapy is appropriate for the individual patient’s physiology and activity level.

Body weight and BMI: annual weight tracking identifies the slow accumulation of weight — 2 to 3 pounds per year — that, over a decade, can meaningfully worsen cardiovascular risk through its effects on blood pressure, blood glucose, inflammatory markers, and sleep apnea severity. Adults with obesity and cardiovascular disease who achieve 5 to 10% weight loss demonstrate significant reductions in blood pressure, HbA1c, triglycerides, and sleep apnea severity. Annual weight measurement and BMI calculation, combined with a waist circumference measurement (above 40 inches in men, above 35 inches in women indicates central adiposity that carries additional metabolic risk), provides the baseline for goal-setting and progress tracking.

Medication Review: Annual Checklist for Heart Medications

Every annual visit should include a comprehensive medication review — a systematic assessment of every medication (prescription and over-the-counter), supplement, and herbal product currently being taken, with attention to whether each is still indicated, appropriately dosed for current kidney and liver function, and producing the intended clinical effect at acceptable side-effect burden. This medication reconciliation is particularly important for older adults taking four or more cardiovascular medications, because drug interactions, dose accumulation from declining kidney function, and evolving clinical status can change the risk-benefit profile of medications that were appropriate when first prescribed but may now warrant adjustment.

The annual medication review should specifically address: current blood pressure control on the existing antihypertensive regimen; whether the current statin dose is achieving the LDL target and whether the patient is tolerating it without significant myopathy or liver enzyme elevation; whether anticoagulation (if prescribed for atrial fibrillation or prior thromboembolism) is being taken consistently and monitored appropriately; whether any medication has been added by a specialist or hospitalist since the last annual visit without primary care awareness; and whether any over-the-counter NSAIDs, decongestants (pseudoephedrine raises blood pressure), or herbal supplements known to affect blood pressure or anticoagulation are being used. Asking the patient to bring all pill bottles to the annual visit — including vitamins, fish oil, herbals, and OTC pain medications — prevents inadvertent drug interactions from being missed.

Lifestyle Assessment: Annual Cardiovascular Lifestyle Review

Diet, physical activity, sleep, and tobacco exposure are the four lifestyle domains that independently and collectively determine cardiovascular risk over decades. An annual structured lifestyle assessment — not just a brief “do you exercise?” inquiry — quantifies current behaviors and identifies the highest-yield modifiable risks for focused counseling and goal-setting. For blood pressure and cholesterol management, lifestyle modification can produce reductions equivalent to a modest dose of a single medication when applied consistently.

Physical activity assessment should quantify minutes per week of aerobic activity and frequency of strength training. Adults meeting the 150 minutes per week of moderate-intensity aerobic activity recommendation have a 30 to 35% lower cardiovascular event rate compared to sedentary adults, independent of other risk factors. For those not meeting this threshold, identifying the specific barrier — joint pain, breathlessness, lack of safe environment, lack of motivation, uncertainty about safe exercise after a cardiac event — allows targeted counseling or referral to physical therapy or cardiac rehabilitation.

Dietary assessment should focus on sodium intake (target below 2,000 mg per day for hypertension and heart failure), saturated fat and trans fat intake (for LDL management), dietary fiber (targeting 25 to 35 grams per day for LDL and glycemic benefit), and alcohol consumption (above 14 drinks per week in men or 7 in women significantly raises blood pressure and atrial fibrillation risk). A single-question sodium assessment (“How often do you eat restaurant food or processed foods in a typical week?”) correlates well with urinary sodium excretion and provides a rapid clinical signal for dietary counseling priority.

Cardiovascular Screening Procedures: What Frequency Is Appropriate

Beyond laboratory tests and physical measurements, several screening procedures deserve inclusion in the annual cardiovascular checklist. A resting 12-lead ECG every one to two years is appropriate for adults with established cardiovascular disease, diabetes, hypertension on multiple medications, or symptoms warranting rhythm assessment — it provides a baseline for comparison if new symptoms develop and can detect asymptomatic atrial fibrillation, conduction disease, or prior silent myocardial infarction. A repeat echocardiogram every two to three years is appropriate for adults with known valvular heart disease (aortic stenosis, mitral regurgitation) or reduced ejection fraction — these conditions progress at predictable rates and serial imaging determines the optimal timing for intervention.

Abdominal aortic aneurysm (AAA) screening with abdominal ultrasound is recommended once for all men aged 65 to 75 who have ever smoked (US Preventive Services Task Force Grade B recommendation). Abdominal aortic aneurysms — dilatation of the aorta above 3 cm — are typically asymptomatic until they rupture, at which point mortality exceeds 80%. Screening identifies aneurysms amenable to elective repair before rupture. For women who smoked and men outside the screening age who have significant risk factors (family history, established vascular disease), selective screening by primary care is appropriate.

Related Topics on Horizon Health Guide

• When Older Adults Should Seek Heart Evaluation — specific symptoms, ECG findings, and risk factor combinations that warrant prompt cardiology referral or emergency evaluation
• Preventive Heart Care for Older Adults — primary and secondary prevention strategies including statin evidence, aspirin guidance, and emerging medications for high-risk patients over 65
• Monitoring Blood Pressure at Home for Seniors — how to measure blood pressure correctly at home and interpret readings in the context of your annual blood pressure management goals
• Heart Disease Risk in Older Adults — the major cardiovascular risk factors targeted by the annual checklist and the evidence-based framework for prioritizing which risks to address first
• Fall Risk, Dizziness, and Heart Medications — annual medication review considerations for older adults on antihypertensives, including orthostatic hypotension monitoring and fall prevention assessment

Clinical References and Further Reading

• ACC/AHA 2019 Primary Prevention Guideline — Circulation 2019: evidence-based framework for annual cardiovascular risk assessment including lipid targets, blood pressure goals, diabetes management, and lifestyle recommendations for adults at all risk levels
• USPSTF AAA Screening Recommendation: one-time abdominal ultrasound screening for abdominal aortic aneurysm in men aged 65 to 75 who have ever smoked, with evidence summary and implementation guidance
• SPRINT Trial — NEJM 2015: intensive blood pressure control (systolic below 120 mmHg) reduced cardiovascular events by 25% compared to standard control in non-diabetic adults over 50, informing current blood pressure targets in the annual cardiovascular checklist

Vaccination and Infection Prevention as Cardiovascular Protection

Annual influenza vaccination reduces the risk of acute myocardial infarction in high-risk cardiac patients by approximately 30 to 40% — a finding replicated across multiple observational studies and supported by the biological plausibility that respiratory infections trigger systemic inflammation, increased platelet aggregation, and arterial plaque destabilization that can precipitate acute coronary syndromes. The cardiovascular benefit of flu vaccination in adults with established heart disease is substantial enough that ACC/AHA heart failure and coronary artery disease guidelines include annual influenza vaccination as a Class I recommendation (highest level of evidence and expert consensus).

COVID-19 vaccination is associated with significant reductions in acute myocardial infarction, stroke, and thromboembolism events following COVID-19 infection — the cardiovascular complications of severe COVID-19 being well-documented. Updated bivalent booster doses available annually should be discussed with your primary care physician, as older adults and those with cardiac comorbidities derive the greatest benefit from updated formulations that address circulating strains.

Pneumococcal vaccination — a two-vaccine series (PCV20 or PCV15 followed by PPSV23) — is recommended for all adults 65 and older because pneumococcal pneumonia is among the infectious illnesses most commonly associated with acute cardiovascular events in older patients. Confirm at your annual visit that your pneumococcal vaccination series is complete and that shingles vaccination (recombinant zoster vaccine, two doses) has been administered — herpes zoster is associated with a transient increase in cardiovascular event risk in older adults that can be prevented with vaccination.

Thyroid Function and Cardiovascular Health

Thyroid dysfunction affects 5 to 10% of adults over 65 and has direct, clinically significant cardiovascular effects that make thyroid function screening an important component of annual cardiovascular health maintenance. Hypothyroidism — underactive thyroid — causes elevated LDL cholesterol, bradycardia, diastolic hypertension, and increased cardiovascular event risk. Hyperthyroidism — overactive thyroid — causes tachycardia, atrial fibrillation, elevated systolic blood pressure, and increased risk of heart failure and stroke. Both conditions may present subtly in older adults without the classic textbook symptoms seen in younger patients.

A thyroid-stimulating hormone (TSH) level is the most sensitive single test for thyroid dysfunction and should be checked every one to two years in all adults over 65 and annually in patients with established cardiovascular disease, atrial fibrillation, or unexplained changes in heart rate, weight, energy, or lipid levels. Subclinical hypothyroidism (elevated TSH with normal free T4) affects approximately 10% of women over 65 and is associated with increased LDL and modest cardiovascular risk — whether treatment is beneficial in patients with TSH above 10 mIU/L and below 10 mIU/L remains an area of ongoing clinical debate, but TSH monitoring allows individualized treatment decisions in consultation with an endocrinologist.

Sleep Quality and Cardiovascular Risk Assessment

Sleep-disordered breathing — primarily obstructive sleep apnea — affects 30 to 40% of adults over 60 and is a recognized independent cardiovascular risk factor that is both clinically underdiagnosed and highly treatable. The annual cardiovascular checklist should include a brief screening for sleep apnea symptoms: loud snoring (confirmed by bed partner if possible), witnessed apneas (partner observes the patient stop breathing during sleep), waking with gasping or choking, excessive daytime sleepiness despite adequate time in bed, and morning headaches. The STOP-Bang questionnaire (Snoring, Tired, Observed apneas, Pressure/hypertension, BMI above 35, Age above 50, Neck circumference above 40 cm, Gender male) — a simple eight-item clinical tool — has high sensitivity for detecting moderate-to-severe sleep apnea that warrants overnight polysomnography or home sleep apnea testing.

Insufficient sleep (less than six hours per night) and poor sleep quality independent of sleep apnea are also associated with elevated cardiovascular risk through their effects on blood pressure variability, sympathetic nervous system activation, and systemic inflammation. Adults reporting consistently poor sleep quality should be asked about sleep hygiene practices (consistent sleep and wake times, avoiding screens and caffeine before bed, darkened sleeping environment), and significant insomnia should be addressed with behavioral cognitive therapy for insomnia (CBT-I) — the first-line treatment for chronic insomnia that has demonstrated greater long-term effectiveness than sleep medications without the side-effect and dependency risks particularly relevant in older adults.

Mental Health and Cardiovascular Outcomes

Depression affects approximately 15 to 20% of adults over 65 with established cardiovascular disease and is associated with a two- to three-fold increase in cardiovascular mortality, increased cardiac events, and substantially impaired quality of life. The PHQ-2 (two-item Patient Health Questionnaire — asking about anhedonia and depressed mood over the previous two weeks) takes less than 60 seconds to administer and identifies patients warranting more comprehensive depression evaluation. Annual depression screening in all adults over 65 is recommended by the United States Preventive Services Task Force. Treatment of depression in cardiac patients — whether through psychotherapy, antidepressant medication, or combined approaches — improves both mental health outcomes and cardiac outcomes, including treatment adherence and exercise participation.

Social isolation and loneliness — conditions affecting approximately 25% of older adults — have cardiovascular risk magnitudes comparable to smoking 15 cigarettes per day, according to analyses of prospective cohort data. Chronic social isolation activates the same inflammatory and sympathetic nervous system pathways that underlie atherosclerosis acceleration. The annual visit provides an opportunity to briefly assess social connectedness and refer isolated older adults to community programs, senior centers, volunteer opportunities, or mental health services. While addressing loneliness may seem outside the traditional scope of cardiovascular medicine, its magnitude as a modifiable cardiovascular risk factor justifies its inclusion in a comprehensive annual heart health review.

Frailty Assessment and Cardiovascular Care

Frailty — a clinical syndrome of reduced physiological reserve and increased vulnerability to stressors — affects approximately 10% of adults over 65 and 25 to 30% of adults over 80. The Fried Frailty Phenotype defines frailty by the presence of three or more of five criteria: unintentional weight loss, exhaustion, weak grip strength, slow walking speed, and low physical activity. Frailty substantially modifies cardiovascular treatment decisions — aggressive blood pressure lowering in a frail older adult may produce orthostatic hypotension, falls, and functional decline that outweigh the long-term blood pressure reduction benefit. Similarly, statin therapy in a frail adult with limited life expectancy and multiple comorbidities may impose myopathy side effects without meaningful cardiovascular event prevention benefit.

Including a brief frailty screening — asking about unintentional weight loss, exhaustion, and walking speed at the annual cardiovascular visit — allows the care team to calibrate treatment intensity appropriately. The annual checklist for a frail 84-year-old with multiple comorbidities will look different from the same checklist applied to a robust, physically active 67-year-old with identical cardiovascular risk factors. Recognizing this difference, and tailoring treatment goals accordingly, is what distinguishes comprehensive cardiovascular care from one-size-fits-all guideline application.